Drugs that contain Erdafitinib

1. Drug name - BALVERSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
May, 2031

(8 years from now)

CN102858765B JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitor
Apr, 2031

(8 years from now)

CN104725362B JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitor
Apr, 2031

(8 years from now)

CN104725362A JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitor
Apr, 2031

(8 years from now)

CN102858765A JANSSEN BIOTECH Pyrazolyl Quinazoline Kinase Inhibitors
Apr, 2031

(8 years from now)

IN201202591P3 JANSSEN BIOTECH Pyrazolyl Quinazoline Kinase Inhibitors
Apr, 2031

(8 years from now)

IN325020B JANSSEN BIOTECH A Process For The Preparation Of A Compound Of Formula (I)
Apr, 2031

(8 years from now)

EP3590934A1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP2563775B1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP3178818B1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP3590934B1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP3178818A1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP2563775A1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors Apr, 2031

(8 years from now)

US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators Mar, 2035

(12 years from now)

US10898482 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine Feb, 2036

(13 years from now)

US11077106 JANSSEN BIOTECH Cancer treatment Feb, 2038

(15 years from now)

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemotherapy, with dosing based on serum phosphate levels

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.